The Dimerix Limited Clinical Trials – ACTION for Diabetic Kidney Disease and ACTION for Focal Segmental Glomerulosclerosis – Are Now Open!
Dimerix Limited is a clinical stage biotechnology company that is listed on the Australian Stock Exchange (ASX:DXB)
Our vision is to positively improve human health by creating safe and effective new treatments for patients with unmet medical needs
Recent news and media
Dimerix now recruiting patients for two phase 2 clinical trials in Diabetic Kidney Disease and a rare kidney scarring orphan disease
For more information please see media release.
Two Posters Presented at ANZSNASM
Dimerix have presented the following two posters at the ANZSNASM conference. ANZSNASM 2018 ACTION for DKD ANZSNASM 2018 ACTION for FSGS [...]
ASX: Dimerix Executive Team Bolstered Through CEO Appointment
Highlights Experienced biotech and pharmaceuticals professional, Dr Nina Webster to join Dimerix as new Chief Executive Offer and Managing Director, commencing [...]